Cervical screening co-testing

Cervical screening co-testing has been studied in 1 paper since 2026: none in people yet; 1 in the past year. No study of it in people or animals has been published yet. The newest paper, Feb 14, 2026: “Cost-effectiveness of policy options for transformation of cytology-based nationwide cervical cancer screening programme in the Czech Republic: model-based economic evaluation”.

Exposure

1 paper studies it3 findingsUpdated

See all 1 papers on cervical screening co-testing

  • In silico1

What did studies of cervical screening co-testing find?

3

Studies of cervical screening co-testing measured 3 outcomes: Incremental cost-effectiveness ratio, cervical cancer mortality and cervical cancer incidence.

Incremental cost-effectiveness ratio

downin silico1

1 study
  1. Cervical screening co-testing decreases incremental cost-effectiveness ratio in silico (Comparison of cervical screening strategies in the Czech Republic) (Lowest ICER among evaluated strategies).

    “The lowest ICER was reported for a strategy combining cytology at two-year intervals and co-testing at four-year intervals from ages 30 to 65.”

    In silicoComparison of cervical screening strategies in the Czech RepublicCytology every two years and co-testing every four yearsfemales

    Cost-effectiveness of policy options for transformation of cytology-based nationwide cervical cancer screening programme in the Czech Republic: model-based economic evaluation

    medRxivPreprint

Cervical cancer mortality

downin silico1

1 study
  1. Cervical screening co-testing decreases cervical cancer mortality in silico.

    “only specific co-testing strategies lead to a decrease in incidence and mortality but differ in benefits and economic efficiency.”

    In silicoSpecific co-testing strategies compared with annual cytology with co-testing at ages 35, 45, and 55 in the Czech Republicfemales

    Cost-effectiveness of policy options for transformation of cytology-based nationwide cervical cancer screening programme in the Czech Republic: model-based economic evaluation

    medRxivPreprint

Cervical cancer incidence

downin silico1

1 study
  1. Cervical screening co-testing decreases cervical cancer incidence in silico.

    “only specific co-testing strategies lead to a decrease in incidence and mortality but differ in benefits and economic efficiency.”

    In silicoSpecific co-testing strategies compared with annual cytology with co-testing at ages 35, 45, and 55 in the Czech Republicfemales

    Cost-effectiveness of policy options for transformation of cytology-based nationwide cervical cancer screening programme in the Czech Republic: model-based economic evaluation

    medRxivPreprint

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 1Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 01 paper in 12 months